Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Risk of biochemical recurrence based on extent and location of positive surgical margins after robot-assisted laparoscopic radical prostatectomy

BMC Cancer201818:1291

https://doi.org/10.1186/s12885-018-5229-1

  • Received: 8 May 2018
  • Accepted: 17 December 2018
  • Published:

The Correction to this article has been published in BMC Cancer 2019 19:124

Open Peer Review reports

Abstract

Background

There are no published studies on the simultaneous effect of extent and location of positive surgical margins (PSMs) on biochemical recurrence (BCR) after robot-assisted laparoscopic prostatectomy (RALP). The aim was to report the incidence, extent, and location of PSMs over the inclusion period as well as the rates of BCR and cancer-related mortality, and determine if BCR is associated with PSM extent and/or location.

Methods

Retrospective review of 530 consecutive patients who underwent RALP between 2003 and 2012. Kaplan-Meier (KM) survival analyses and Cox regressions were performed to determine variables associated with BCR.

Results

For the 530 operated patients, evaluated at a median of 92 months (IQR, 87–99), PSMs were observed in 156 (29%), of which 24% were focal. Out of 172 PSMs, 126 (73%) were focal and 46 (27%) were extensive. The KM survival using BCR as endpoint was 0.81 (CI, 0.78–0.85) at 5 years and was 0.67 (CI, 0.61–0.72) at 10 years; and using cancer-related mortality as endpoint was 0.99 (CI, 0.99–1.00) at 5 years and 0.95 (CI, 0.92–0.98) at 10 years. Multi-variable analysis revealed the strongest predictors of BCR to be Gleason score ≥ 8 (HR = 7.97; CI, 4.38–14.51) and 4 + 3 (HR = 3.88; CI, 2.12–7.07), lymph nodes invasion (HR = 3.42; CI, 1.70–6.91), pT stage 3b or 4 (HR = 3.07; CI, 1.93–4.90), and extensive apical PSMs (HR = 2.62; CI, 1.40–4.90) but not focal apical PSMs (HR = 0.86; CI, 0.49–1.50; p = 0.586).

Conclusion

Extensive apical PSMs significantly increased the risk of BCR, independently from pT stage, Gleason score and lymph nodes invasion, while focal apical PSMs had no significant effect on BCR.

Keywords

  • Prostate cancer
  • Prostatectomy
  • Robot-assisted
  • Laparoscopy
  • Biochemical recurrence
  • Positive surgical margins

Background

Positive surgical margins (PSMs) following radical prostatectomy are adverse outcomes, associated with the risk of biochemical recurrence (BCR) [1, 2]. Recent studies report a wide range of PSM incidence (12–39%) [38] which depends on tumor size, stage and localization, as well as surgeon experience [6, 9], and surgical approach [3, 10, 11].

The impact of PSM status on BCR is controversial: First, multifocal PSMs indicate that there is more cancer tissue left behind, but are not always associated with an increased risk of BCR [1017]. Second, extensive PSMs increase the risk of BCR [2, 14, 15], even if the lack of consensus in reporting extent does not allow firm conclusions [1]. Third, apical and posterolateral PSMs are believed to present a greater risk of BCR than other locations [4, 5, 15, 18], though numerous studies found that location does not affect prognosis [4, 19]. Whatever their oncologic implications, PSMs often cause anxiety in affected patients, and could prompt adjuvant radiotherapy [2].

While some studies investigated the associations between BCR and PSM extent and location [4, 5], none considered their simultaneous effect. The authors therefore aimed to: (i) report the variations of incidence, extent, and location of PSMs following robot-assisted laparoscopic prostatectomy (RALP) over the inclusion period; (ii) report the rates of BCR and cancer-related mortality at 2, 5, and 10 years; and (iii) determine if BCR is associated with PSM extent and/or location independently from pathologic stage and Gleason score.

Methods

Study design

The authors retrospectively studied the records of all 530 consecutive patients (File1) that underwent RALP, between 2003 and 2012, all performed or supervised by the senior surgeon in a single center (CHR). The inclusion criteria were localized prostate cancer (cT1 to cT3). All patients provided written informed consent for their participation in this study. In addition to their routine follow-up (FU) visits, all patients were contacted to update their records and measure their prostate-specific antigen (PSA) serum levels, between 2015 and 2017. Unless confirmed to be deceased, patients who were not evaluated during this time interval were considered lost to follow-up (LTFU).

Pre-operative evaluation

Pre-operative data included: age at diagnosis. PSA serum level, biopsy Gleason score and tumour clinical stage (cT) by rectal and imaging examinations (Table 1).
Table 1

Demographics, preoperative and pathological data

 

Total

Evaluated

Lost to FU

p-value

n = 530

c

n = 77

Follow-up (months) - median (IQR)

  

92

(87–99)

47

(29–87)

 

Preoperative data

  

  Age (years) - median (IQR)

63

(58–68)

63

(59–68)

61

(56–66)

0.028

  Preoperative PSA - median (IQR)

6.4

(4.8–9.0

6.6

(4.9–9.0)

6.0

(4.7–9.2)

0.628

  cT stage

 

0.019

   T1 (a,b,c)

199

(38%)

175

(39%)

24

(31%)

 

   T2a

106

(20%)

82

(18%)

24

(31%)

 

   T2b

155

(29%)

136

(30%)

19

(25%)

 

   T2c

52

(10%)

48

(11%)

4

(5%)

 

   T3

11

(2%)

9

(2%)

2

(3%)

 

   unknown

7

(1%)

3

(1%)

4

(5%)

 

  D’Amico risk group

 

0.005

   low

225

(42%)

205

(45%)

20

(26%)

 

   intermediary

196

(37%)

152

(34%)

44

(57%)

 

   high

97

(18%)

85

(19%)

12

(16%)

 

   unknown

12

(2%)

11

(2%)

1

(1%)

 

  Nerve sparing

 

0.471

   unilateral

13

(2%)

12

(3%)

1

(1%)

 

   bilateral

498

(94%)

429

(95%)

69

(90%)

 

   unknown

19

(4%)

12

(3%)

7

(9%)

 

Pathological results

  

 Pathological Gleason Score

 

0.005

    ≤ 6

214

(40%)

171

(38%)

43

(56%)

 

   3 + 4

178

(34%)

159

(35%)

19

(25%)

 

   4 + 3

73

(14%)

64

(14%)

9

(12%)

 

    ≥ 8

58

(11%)

55

(12%)

3

(4%)

 

   unknown

7

(1%)

4

(1%)

3

(4%)

 

  pT stage

      

0.004

   pT2

385

(73%)

321

(71%)

64

(83%)

 

   pT3a

80

(15%)

75

(17%)

5

(6%)

 

   pT3b

56

(11%)

52

(11%)

4

(5%)

 

   pT4

2

(0%)

2

(0%)

0

(0%)

 

   unknown

7

(2%)

3

(1%)

4

(5%)

 

  Involvment of lymph nodes

13

(2%)

12

(3%)

1

(1%)

0.483

  Positive surgical margins

  

   Apical

       

    focal

53

(10%)

43

(9%)

10

(13%)

0.194

    extensive

19

(4%)

19

(4%)

0

(0%)

0.054

   Posterolateral

       

    focal

44

(8%)

39

(9%)

5

(6%)

0.604

    extensive

20

(4%)

18

(4%)

2

(3%)

0.454

   Base

       

    focal

26

(5%)

22

(5%)

4

(5%)

0.840

    extensive

7

(1%)

7

(2%)

0

(0%)

na*

   Bladder neck

       

    focal

3

(1%)

2

(0%)

1

(1%)

na*

    extensive

0

(0%)

0

(0%)

0

(0%)

na*

*Not applicable, sample size too small

Surgical technique

A 3-arm Da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) was used from 2003 to 2006 and was upgraded to a higher definition 4-arm system in January 2007 [20].

Pathological evaluation

Prostate specimens were fixed in paraffin and prepared following the Stanford protocol [21]. Information collected included: pathologic stage of the tumour (pT), pathologic Gleason score, the presence of PSMs, defined as cancer glands observed at the inked surface of prostate specimens, and lymph nodes invasion (pN). The location of PSMs was defined as either apical, posterolateral, basal or at bladder neck. The extent of PSMs was noted as either focal (≤3 mm) or extensive (> 3 mm).

Postoperative follow-up

For patients with undetectable PSA (< 0.1 ng/ml) at 6 weeks, PSA levels were measured every 6 months in the first 2 years, and once every year thereafter. BCR was defined by PSA > 0.2 ng/ml confirmed by two successive assays at any point during follow-up. None of the patients received adjuvant treatments, salvage treatments were only considered for patients with BCR.

Statistical analysis

Categorical variables were described using numbers and percentages. Continuous variables were described using median, 95% confidence interval (CI) and inter-quartile range (IQR). Differences between patients evaluated after 2015 and those LTFU were assessed using Chi-2 tests or Fisher’s exact tests, where appropriate. Kaplan-Meier (KM) survival was estimated at 2, 5 and 10 years for two different endpoints: (i) BCR and (ii) cancer-related mortality. To account for competing risks, the cumulative incidence function was also used and revealed that the KM method exaggerated the incidence of BCR by only 0.8% at 10 years, which was deemed negligible. Uni- and multi-variable Cox regressions were performed, following the rule of a minimum of 10 events per variable (EPV) [22, 23],to determine associations of BCR with age, preoperative PSA, year of treatment, pathologic Gleason Score (≤6, 3 + 4, 4 + 3, ≥8), stage pT (pT2, pT3a, pT3b, pT4), lymph nodes invasion (none/ metastasized), as well as location and extent of PSM. Variables included in the final multi-variable model were identified by backward selection using the Akaike Information Criterion. Statistical analyses were performed using R version 3.4.1 (R Foundation, Vienna, Austria). The level of significance was set at p < 0.05.

Results

For the cohort of 530 patients operated, PSMs were observed in 156 (29%) patients, of which 18 (3%) had two or more PSMs (Additional file 1). Out of 172 PSMs, 126 (73%) were focal and 46 (27%) were extensive. The location of PSMs was apical in 72 (14%), posterolateral in 64 (12%), basal in 33 (6%), and at the bladder neck in 3 (1%) (Table 1). Patients at stage pT3a 57%) and pT3b/4 (72%) had a far greater incidence of PSMs than patients at stage pT2 (23%). The overall PSMs rates decreased from 38 to 18% over the inclusion period (Fig. 1). A total of 77 patients were lost to FU, leaving 453 for clinical evaluation at a median FU of 92 months (IQR, 87–99). Compared to patients evaluated, those LTFU comprised (Table 1) had similar proportion of high-risk tumors (16% vs. 19%; p = 0.504), and of extensive apical PSMs (0% vs 4%; p = 0.067), but a lower proportion of tumors at pT stage ≥3 (12% vs. 28%; p = 0.002).
Fig. 1
Fig. 1

Incidence of posterior surgical margins (PSM) over the inclusion period

From the cohort of 453 patients evaluated, 138 (30%) had a BCR, of which 10 (2%) died of causes directly related to prostate cancer, and 9 (2%) died from unrelated causes. Compared to recurrence-free patients, patients who had BCR comprised (i) a higher proportion of pathological Gleason score ≥ 4 + 3 (49% vs. 17%; p < 0.001), (ii) a higher proportion of tumors at pT stage ≥3 (53% vs. 18%; p < 0.001), and (iii) a higher proportion of extensive PSMs (20% vs 5%; p < 0.001) (Table 2). Using BCR as endpoint, the KM survival at 2 years was 0.91 (CI, 0.88–0.93), at 5 years was 0.81 (CI, 0.78–0.85) and at 10 years was 0.67 (CI, 0.61–0.72). Using cancer-related mortality as endpoint, the KM survival at 2 years was 1.00 (CI, 1.00–1.00), at 5 years was 0.99 (CI, 0.99–1.00) and at 10 years was 0.95 (CI, 0.92–0.98) (Fig. 2).
Table 2

Comparison of patients with and without biochemical recurrence

 

Recurrence-free n = 315

Biochemical Recurrence n = 138

Preoperative data

Age – median (IQR)

63.0 (58.0–68.0)

64.0 (59.0–69.0)

Preoperative PSA – median (IQR)

6.0 (4.5–8.0)

8.0 (5.9–10.9)

Pathological results

Pathological Gleason Score

 ≤6

150 (48%)

21 (15%)

 3 + 4

113 (36%)

46 (33%)

 4 + 3

33 (10%)

31 (22%)

 > 8

19 (6%)

36 (26%)

 unknown

0 (0%)

3 (2%)

pT stage

 pT2

259 (82%)

62 (45%)

 pT3a

40 (13%)

35 (25%)

 pT3b

16 (5%)

36 (26%)

 pT4

0 (0%)

2 (1%)

 unkwon

0 (0%)

3 (2%)

 Involvment of lymph nodes

2 (1%)

10 (7%)

Positive surgical margins

 Apical

  

 focal

29 (9%)

14 (10%)

 extensive

6 (2%)

13 (9%)

Posterolateral

 focal

18 (6%)

21 (15%)

 extensive

7 (2%)

11 (8%)

Base

 focal

11 (3%)

11 (8%)

 extensive

4 (1%)

3 (2%)

Bladder neck

 focal

1 (0%)

1 (1%)

 extensive

0 (0%)

0 (0%)

Fig. 2
Fig. 2

Kaplan-Meier survival curves for the initial cohort of 530 patients using two endpoints: (a) biochemical recurrence and (b) cancer-specific mortality

Univariable Cox regressions revealed BCR to be significantly associated with age at diagnosis (p = 0.015), preoperative PSA level (p < 0.001), year of treatment (p = 0.01); pathological Gleason score (p < 0.001), pT stage (p < 0.001), the lymph nodes invasion (p < 0.001) as well as the presence of focal posterolateral and base PSMs (respectively, p < 0.001 and p = 0.003) and extensive apical and posterolateral PSMs (respectively, p < 0.001 and p = 0.002) (Table 3). Multi-variable Cox regression revealed the strongest predictors of BCR to be Gleason score ≥ 8 (HR = 7.97; CI, 4.38–14.51; p < 0.001) and 4 + 3 (HR = 3.88; CI, 2.12–7.07; p < 0.001) compared to Gleason score ≤ 6, followed by lymph nodes invasion (HR = 3.42; CI, 1.70–6.91; p < 0.001), pT stage 3b or 4 (HR = 3.07; CI, 1.93–4.90; p < 0.001) compared to pT stage 2, and extensive apical PSMs (HR = 2.62; CI, 1.40–4.90; p = 0.003) but not focal apical PSMs (HR = 0.86; CI, 0.49–1.50; p = 0.586).
Table 3

Uni- and multi-variable Cox regressions of factors associated with biochemical recurrence

 

Univariable

Multivariable

HR

95% CI

p-value

HR

95%

p-value

Age

1.03

(1.01–1.06)

0.015

 

Preop PSA

1.02

(1.01–1.03)

< 0.001

 

Year of treatment

1.10

(1.02–1018)

0.012

 

Pathological Gleason Score

 ≤6

REF

  

REF

  

 3 + 4

3.36

(2.00–5.64)

< 0.001

2.86

(1.68–4.88)

< 0.001

 4 + 3

7.21

(4.13–12.60)

< 0.001

3.88

(2.12–7.07)

< 0.001

 ≥8

13.75

(7.96–23.74)

< 0.001

7.97

(4.38–14.51)

< 0.001

Stage pT

 pT2

REF

  

REF

  

 pT3a

3.12

(2.06–4.73)

< 0.001

2.28

(1.48–3.52)

< 0.001

 pT3b & pT4a

7.37

(4.89–11.12)

< 0.001

3.07

(1.93–4.90)

< 0.001

 Involvment of lymph nodes

8.84

(4.57–17.12)

< 0.001

3.42

(1.70–6.91)

< 0.001

Apical margins

 focal

1.10

(0.63–1.92)

0.742

0.86

(0.49–1.50)

0.586

 extensive

3.80

(2.13–6.77)

< 0.001

2.62

(1.40–4.90)

0.003

Posterolateral margins

 focal

2.59

(1.62–4.14)

< 0.001

 

 extensive

2.73

(1.46–5.08)

0.002

 

Base margins

 focal

2.60

(1.40–4.84)

0.003

 

 extensiveb

1.45

(0.46 – 4.58)

0.525

 

Neck margins

 focal

1.55

(0.21–10.98)

0.67

 

 extensivec

aOnly 2 patients were at stage pT4, both of which had biochemical recurrence

bOnly 7 patients had extensive base margins, 3 of which had biochemical recurrence

cNone of the patients had extensive neck margins

Discussion

The principal finding of this study was that BCR was independently associated with extensive apical PSMs but not with focal apical PSMs, in addition to Gleason score (≥ 8 and 4 + 3), lymph nodes invasion, and pT stage (pT3b/pT4). This observation is important because the prostate apex is the most frequent PSM site for all radical prostatectomy approaches [24, 25]. There are several explanations as to why focal apical PSMs may be frequent but do not influence oncologic outcomes. First, the proximity of the urethral sphincter, neurovascular bundles and dorsal venous complex renders cancer excision at the apex most challenging for surgeons. Second, the variable configuration of the apex frequently causes iatrogenic intra-prostatic incisions, hypothetically leading to the creation of artefacts or ‘false’ PSMs [26]. Third, the sparse capsule and periprostatic tissue at the apex makes it difficult for histopathologists to distinguish intra-prostatic from extra-prostatic cancers [1].

Recent studies [27, 28] demonstrated that patients with PSMs have a higher risk of BCR and clinical progression but not necessarily of cancer-specific mortality. At a median follow-up of 92 months (IQR, 87–99), our BCR rate was 30% and cancer-specific mortality was 2%, both of which are within the range reported in recent studies [36, 8, 14, 1618, 29]. At 10 years, our KM survival was respectively 67 and 89%, using BCR and cancer-specific death as endpoints, respectively.

It has been suggested that apical PSMs occur due to factors other than cancer aggressiveness, although their benign nature remains widely disputed [5, 30]. Our findings explain this controversy, which is likelydue to lack of distinction between focal and extensive PSMs at the apex. This further demonstrates the importance of adopting a standard method to report PSMs, including their precise extent and location [28]. The finding that focal apical PSMs are not associated with BCR is important, as it could help surgeons improve functional outcomes by sparing the sphincter, and could improve prognosis and decisions regarding additional radiotherapy (RT) [1, 2, 9]. The current rationale for administering local therapy is dichotomous: some advocate adjuvant RT immediately after surgery to all men with PSMs, others advocate salvage RT selectively to men if and when BCR is detected [2]. Our findings suggest that risk of BCR differs depending on PSMs location and extent, which should therefore be taken into account when considering adjuvant RT. In our series, multivariable analysis did not find extensive PSMs at other locations than the apex to be associated with BCR, likely due to the small number of observations in each subgroup. We recorded length of PSMs only as a categorical variable: focal (< 3 mm) or extensive (≥3 mm), [31] though the use of a continuous variable would have been more accurate and objective [32].

For the total cohort of 530 patients, PSMs were observed in 156 (29%) patients, of which 18 had two or more PSMs. The incidence of PSMs reported in recent radical prostatectomy series varies widely (12–35%) [36, 8, 14, 1618, 29], partly due to the large inter-observer variability in identifying PSMs [28], and is also related to surgical experience [3, 6, 9, 12, 13]. For instance, in their study of 1701 RALPs, Sivaraman et al. [6] described a sharp decrease of PSM incidence from 25 to 20% after the first 350 patients. Sooriakumaran et al. [3] demonstrated continued improvements with increasing surgeon experience, estimating that over 1600 cases are required to decrease PSM rates below 10%. The observed rates of overall PSMs reduced over our inclusion period (Fig. 1). Extensive PSMs rates decreased drastically, immediately after the first 150 patients, while focal PSMs rates decreased more progressively, possibly due to their greater technical challenge.

The present study is limited by its small cohort size, which could influence our conclusions due to limited statistical power; we however respected the accepted rule of 10 events per variable [22, 23] for the Cox model. Although a non-negligible number of patients were lost to FU, they presented a less severe pathological profile (Table 1). Other limitations include lack of report of tumor volume, of Gleason score at PSM and of anterior margins, which were categorized as either basal, posterolateral or apical. Notwithstanding these limitations, the present study comprises a sizeable monocentric RALP series with adequate follow-up and account for surgical experience.

Conclusion

Our study is the first to investigate the combined effects of PSM location and extent, after robotic assisted radical prostatectomy, and found that the risk of biochemical recurrence increased in the presence of extensive apical margins, independently of pathological Gleason score, pT stage, and lymph nodes invasion. In contrast, the presence of a focal apical margin did not increase the risk of biochemical recurrence. Our findings suggest that adjuvant radiotherapy should only be administered selectively depending on risk factors, including margin location and extent.

Notes

Abbreviations

BCR: 

BioChemical recurrence

CI: 

Confidence interval

cT: 

clinical stage of the tumor

FU: 

Follow-up

HR: 

Hazard ratio

IQR: 

InterQuartile range

KM: 

Kaplan-meier

LTFU: 

Lost to follow-up

PSM: 

Positive surgical margin

pT: 

Pathological stage of the tumor

RALP: 

Robot-assisted radical prostatectomy

Declarations

Acknowledgements

The authors are grateful to Mr. Luca Nover for his assistance with data management, tables preparation and reference formatting.

Funding

MG received a mobility grant from University of Lille-2; AM and GH received fees from ReSurg SA for statistical analysis and manuscript preparation, and CHR was funded by Beaulieu Medical Society (SMB). None of these funding bodies interfered with the study design, data collection, analysis or interpretation of data of this study.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

GM: Conception and design of the study, data management and statistical analysis, drafting and revising the manuscript, and final approval of the manuscript. AM: Analysis and interpretation of data, drafting and revising the manuscript, and final approval of the manuscript. GH: Analysis and interpretation of data, data management and statistical analysis, drafting and revising the manuscript, and final approval of the manuscript. JR: Acquisition of data, drafting and revising the manuscript, and final approval of the manuscript. JS: Acquisition of data, drafting and revising the manuscript, and final approval of the manuscript. AV: Analysis and interpretation of data, drafting and revising the manuscript, and final approval of the manuscript. MS: Analysis and interpretation of data, drafting and revising the manuscript, and final approval of the manuscript. CHR: Acquisition of data, conception and design of the study, drafting and revising the manuscript, and final approval of the manuscript.

Competing interest

The author declares that they have no competing interests.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics committee approval was obtained from the Commission de Déontologie (Genève). Written informed consent was obtained from all individual participants included in the study.

Consent for publication

N/A

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Urology Department, CHU Lille, F-59000 Lille, France
(2)
University of Lille, GIVRE - MERCS - Module for Education and Research Collaboration in Statistics, F-59000 Lille, France
(3)
ReSurg SA, chemin de la Vuarpillière 35, 1260 Nyon, Switzerland
(4)
Orthopaedic Research Laboratory, Radboud University Medical Center, PO, Box 9101, 6500HB, Nijmegen, The Netherlands
(5)
Urology Department, Clinique Générale Beaulieu, 1204 Genève, Switzerland

References

  1. Sooriakumaran P, Dev HS, Skarecky D, Ahlering T. The importance of surgical margins in prostate cancer. J Surg Oncol. 2016;113(3):310–5.View ArticleGoogle Scholar
  2. Yossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol. 2014;65(2):303–13.View ArticleGoogle Scholar
  3. Sooriakumaran P, John M, Wiklund P, Lee D, Nilsson A, Tewari AK. Learning curve for robotic assisted laparoscopic prostatectomy: a multi-institutional study of 3794 patients. Minerva urologica e nefrologica The Italian journal of urology and nephrology. 2011;63(3):191–8.PubMedGoogle Scholar
  4. Sooriakumaran P, Ploumidis A, Nyberg T, Olsson M, Akre O, Haendler L, et al. The impact of length and location of positive margins in predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years. BJU Int. 2015;115(1):106–13.View ArticleGoogle Scholar
  5. Dev HS, Wiklund P, Patel V, Parashar D, Palmer K, Nyberg T, et al. Surgical margin length and location affect recurrence rates after robotic prostatectomy. Urologic oncology. 2015;33(3):109 e7–13.View ArticleGoogle Scholar
  6. Sivaraman A, Sanchez-Salas R, Prapotnich D, Yu K, Olivier F, Secin FP, et al. Learning curve of minimally invasive radical prostatectomy: Comprehensive evaluation and cumulative summation analysis of oncological outcomes. Urologic oncology. 2017;35(4):149.e1–6.View ArticleGoogle Scholar
  7. Seo WI, Kang PM, Yoon JH, Kim W, Chung JI. Correlation between postoperative prostate-specific antigen and biochemical recurrence in positive surgical margin patients: single surgeon series. Prostate international. 2017;5(2):53–8.View ArticleGoogle Scholar
  8. Rouanne M, Rode J, Campeggi A, Allory Y, Vordos D, Hoznek A, et al. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years of follow-up. Scandinavian journal of urology. 2014;48(2):131–7.View ArticleGoogle Scholar
  9. Matulewicz RS, Tosoian JJ, Stimson CJ, Ross AE, Chappidi M, Lotan TL, et al. Implementation of a surgeon-level comparative quality performance review to improve positive surgical margin rates during radical prostatectomy. J Urol. 2017;197(5):1245–50.View ArticleGoogle Scholar
  10. Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP, Shemshaki H. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World journal of urology; 2018.View ArticleGoogle Scholar
  11. Srougi V, Bessa J Jr, Baghdadi M, Nunes-Silva I, da Costa JB, Garcia-Barreras S, et al. Surgical method influences specimen margins and biochemical recurrence during radical prostatectomy for high-risk prostate cancer: a systematic review and meta-analysis. World J Urol. 2017;35(10):1481–8.View ArticleGoogle Scholar
  12. Damani A, Van Hemelrijck M, Wulaningsih W, Crawley D, Cahill D. Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy. World J Urol. 2017;35(1):35–43.View ArticleGoogle Scholar
  13. Park J, Yoo DS, Song C, Park S, Park S, Kim SC, et al. Comparison of oncological outcomes between retropubic radical prostatectomy and robot-assisted radical prostatectomy: an analysis stratified by surgical experience. World J Urol. 2014;32(1):193–9.View ArticleGoogle Scholar
  14. Pettenati C, Neuzillet Y, Radulescu C, Herve JM, Molinie V, Lebret T. Positive surgical margins after radical prostatectomy: what should we care about? World J Urol. 2015;33(12):1973–8.View ArticleGoogle Scholar
  15. Ploussard G, Drouin SJ, Rode J, Allory Y, Vordos D, Hoznek A, et al. Location, extent, and multifocality of positive surgical margins for biochemical recurrence prediction after radical prostatectomy. World J Urol. 2014;32(6):1393–400.View ArticleGoogle Scholar
  16. Somford DM, van Oort IM, Cosyns JP, Witjes JA, Kiemeney LA, Tombal B. Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy. World J Urol. 2012;30(1):105–10.View ArticleGoogle Scholar
  17. Tasci AI, Tufek I, Gumus E, Canda AE, Tugcu V, Atug F, et al. Oncologic results, functional outcomes, and complication rates of robotic-assisted radical prostatectomy: multicenter experience in Turkey including 1,499 patients. World J Urol. 2015;33(8):1095–102.View ArticleGoogle Scholar
  18. Porpiglia F, Fiori C, Manfredi M, Grande S, Poggio M, Bollito E, et al. Surgical margin status of specimen and oncological outcomes after laparoscopic radical prostatectomy: experience after 400 procedures. World J Urol. 2012;30(2):245–50.View ArticleGoogle Scholar
  19. Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, et al. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. BJU Int. 2013;111(6):921–7.View ArticleGoogle Scholar
  20. Rochat CH, Sauvain J, Dubernard P, Hebert AE, Kreaden U. Mid-term biochemical recurrence-free outcomes following robotic versus laparoscopic radical prostatectomy. J Robot Surg. 2011;5(4):251–7.View ArticleGoogle Scholar
  21. McNeal JE, Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate. 2001;49(1):48–57.View ArticleGoogle Scholar
  22. Austin PC, Allignol A, Fine JP. The number of primary events per variable affects estimation of the subdistribution hazard competing risks model. J Clin Epidemiol. 2017;83:75–84.View ArticleGoogle Scholar
  23. Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. J Clin Epidemiol. 2016;76:175–82.View ArticleGoogle Scholar
  24. Meeks JJ, Eastham JA. Radical prostatectomy: positive surgical margins matter. Urol Oncol. 2013;31(7):974–9.View ArticleGoogle Scholar
  25. Patel VR, Coelho RF, Rocco B, Orvieto M, Sivaraman A, Palmer KJ, et al. Positive surgical margins after robotic assisted radical prostatectomy: a multi-institutional study. J Urol. 2011;186(2):511–6.View ArticleGoogle Scholar
  26. Walz J, Burnett AL, Costello AJ, Eastham JA, Graefen M, Guillonneau B, et al. A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol. 2010;57(2):179–92.View ArticleGoogle Scholar
  27. Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, et al. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014;65(4):675–80.View ArticleGoogle Scholar
  28. Maxeiner A, Magheli A, Johrens K, Kilic E, Braun TL, Kempkensteffen C, et al. Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus. BJU Int. 2016;118(5):750–7.View ArticleGoogle Scholar
  29. Yuksel M, Karamik K, Anil H, Islamoglu E, Ates M, Savas M. Factors affecting surgical margin positivity in robotic assisted radical prostatectomy. Arch Ital Urol Androl. 2017;89(1):71–4.View ArticleGoogle Scholar
  30. Suardi N, Gallina A, Lista G, Gandaglia G, Abdollah F, Capitanio U, et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol. 2014;65(3):546–51.View ArticleGoogle Scholar
  31. Stephenson AJ, Wood DP, Kattan MW, Klein EA, Scardino PT, Eastham JA, et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol. 2009;182(4):1357–63.View ArticleGoogle Scholar
  32. van Oort IM, Bruins HM, Kiemeney LA, Knipscheer BC, Witjes JA, Hulsbergen-van de Kaa CA. The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy. Histopathology. 2010;56(4):464–71.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019
corrected publication February/2019

Advertisement